Medtronic's Antibacterial Envelope Effective In Reducing Infections In Cardiac Device Patients With Hematomas

Loading...
Loading...
  • Medtronic plc MDT has announced new data from the WRAP-IT study published in Heart Rhythm.
  • The study evaluated Tyrx absorbable antibacterial envelope, an absorbable, single-use device that holds a cardiac implantable electronic device or implanted neurostimulator.
  • It is designed to stabilize the device after implantation while releasing antibacterial agents, minocycline, and rifampin, over a minimum of seven days.
  • Data demonstrated a significantly lower infection risk for patients who develop hematomas after cardiac implantable electronic devices (CIEDs) when the Tyrx Envelope is used at implant. 
  • The analysis showed an 82% reduction in major CIED infections among patients with the TYRX Envelope who developed hematomas compared to patients in the control group who developed hematomas.
  • Through 36 months of follow-up, there was an over 11-fold increase in the risk of major infection in the control group among patients with hematoma vs. those without hematoma (13.1% vs. 1.6%).
  • WRAP-IT compared the incidence of major infections in patients whose CIED implantation included the Tyrx Envelope (3,495) and patients whose procedure did not (3,488), with follow-up through 12 months. 
  • Price Action: MDT shares are down 0.58% at $127.79 during the market session on the last check Monday.
Posted In: NewsHealth CareGeneralBriefsHematomas
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...